Business
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-
About this update from Sana Biotechnology, Inc.
[{"type":"image","alt":"Sana Biotechnology, Inc","displaySize":"","headline":null,"caption":"Sana Biotechnology, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PW1btp2owOxzuDhhLJX9Mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e","width":300,"height":85}},"lazy":false},{"type":"text","content":"SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics.","length":543,"tagName":"p"},{"type":"text","content":"“I am thrilled to welcome Brian to Sana and to our leadership team,” said Steve Harr, President and Chief Executive Officer of Sana. “He brings deep expertise in capital formation and disciplined capital allocation along with a proven track record of driving financial and operational excellence. Over the next 12-18 months, we expect to generate initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease, helping us better understand these therapies and creating important value inflection points for the company. We have meaningful momentum in our type 1 diabetes and in vivo CAR T programs, and his leadership will be critical as we continue to advance our portfolio, optimize long‑term value creation, and work to deliver these transformative therapies for patients.”","length":819,"tagName":"p"},{"type":"text","content":"Mr. Piper was previously Chief Financial Officer of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and thereafter was Chief Financial Officer of Antares Therapeutics, following its spin-off from Scorpion. Prior to that, he was Chief Financial Officer of Prelude Therapeutics, a public biotech company. Earlier, he served as Chief Financial O...